Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Paxilline (HB1056)
Description:Potent, reversible, selective KCa channel inhibitor. Also SERCA inhibitor.
Purity:>98%
Riluzole (HB6093)
Description:Na+ channel blocker / glutamate inhibitor. TREK-1 K2P channel activator.
Purity:>98%
Spadin (HB5438)
Description:Potent TREK-1/ K2P2.1 channel blocker. Shows fast-acting antidepressant effects.